NASDAQ:NRXS NeurAxis (NRXS) Stock Price, News & Analysis $2.77 +0.01 (+0.36%) Closing price 04:00 PM EasternExtended Trading$2.78 +0.00 (+0.18%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About NeurAxis Stock (NASDAQ:NRXS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NeurAxis alerts:Sign Up Key Stats Today's Range$2.76▼$2.9250-Day Range$2.27▼$3.9952-Week Range$1.33▼$6.20Volume23,387 shsAverage Volume744,296 shsMarket Capitalization$19.99 millionP/E RatioN/ADividend YieldN/APrice Target$7.00Consensus RatingBuy Company Overview NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana. Read More NeurAxis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreNRXS MarketRank™: NeurAxis scored higher than 49% of companies evaluated by MarketBeat, and ranked 592nd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingNeurAxis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageNeurAxis has only been the subject of 1 research reports in the past 90 days.Read more about NeurAxis' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of NeurAxis is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NeurAxis is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about NeurAxis' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.43% of the float of NeurAxis has been sold short.Short Interest Ratio / Days to CoverNeurAxis has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeurAxis has recently decreased by 12.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurAxis does not currently pay a dividend.Dividend GrowthNeurAxis does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.43% of the float of NeurAxis has been sold short.Short Interest Ratio / Days to CoverNeurAxis has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NeurAxis has recently decreased by 12.84%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for NRXS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, NeurAxis insiders have sold 131.00% more of their company's stock than they have bought. Specifically, they have bought $800,001.00 in company stock and sold $1,847,986.00 in company stock.Percentage Held by Insiders15.20% of the stock of NeurAxis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.77% of the stock of NeurAxis is held by institutions.Read more about NeurAxis' insider trading history. Receive NRXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NeurAxis and its competitors with MarketBeat's FREE daily newsletter. Email Address NRXS Stock News HeadlinesNeurAxis, Inc. (NASDAQ:NRXS) Major Shareholder Acquires $800,001.00 in StockJuly 4, 2025 | insidertrades.comNeuraxis ends Masimo license agreement and launches employee stock planJuly 5, 2025 | investing.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.July 25 at 2:00 AM | Porter & Company (Ad)NeurAxis, Inc. Ends Agreement with Masimo CorporationJuly 3, 2025 | tipranks.comNeurAxis, Inc. (NRXS) Latest Stock News & Headlines - Yahoo FinanceJuly 2, 2025 | finance.yahoo.comNeurAxis, Inc. Expands Insurance Coverage for IB-Stim Therapy, Enhancing Access for Patients with Abdominal PainJune 17, 2025 | quiverquant.comQNeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered LivesJune 17, 2025 | globenewswire.comNeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBSJune 10, 2025 | finance.yahoo.comSee More Headlines NRXS Stock Analysis - Frequently Asked Questions How have NRXS shares performed this year? NeurAxis' stock was trading at $2.35 on January 1st, 2025. Since then, NRXS stock has increased by 17.9% and is now trading at $2.77. How were NeurAxis' earnings last quarter? NeurAxis, Inc. (NASDAQ:NRXS) posted its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.25) earnings per share for the quarter. The business had revenue of $0.67 million for the quarter. When did NeurAxis IPO? NeurAxis (NRXS) raised $7 million in an IPO on Wednesday, August 9th 2023. The company issued 1,098,667 shares at a price of $6.00 per share. Who are NeurAxis' major shareholders? Top institutional shareholders of NeurAxis include Wealthcare Advisory Partners LLC (0.21%). View institutional ownership trends. How do I buy shares of NeurAxis? Shares of NRXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of NeurAxis own? Based on aggregate information from My MarketBeat watchlists, some other companies that NeurAxis investors own include AutoZone (AZO), Intel (INTC), Meta Platforms (META), Outdoor (POWW), SPDR S&P 500 ETF Trust (SPY), TJX Companies (TJX) and ETRACS Crude Oil Shares Covered Call ETN (USOI). Company Calendar Last Earnings11/12/2024Today7/25/2025Next Earnings (Estimated)8/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Electromedical equipment Sub-IndustryMedical Equipment Current SymbolNASDAQ:NRXS CIK1933567 Webneuraxis.com Phone(812) 689-0791FaxN/AEmployees19Year FoundedN/APrice Target and Rating Average Price Target for NeurAxis$7.00 High Price Target$7.00 Low Price Target$7.00 Potential Upside/Downside+152.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.63 million Net Margins-492.76% Pretax Margin-341.35% Return on EquityN/A Return on Assets-641.25% Debt Debt-to-Equity RatioN/A Current Ratio0.24 Quick Ratio0.23 Sales & Book Value Annual Sales$2.93 million Price / Sales6.81 Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-10.26Miscellaneous Outstanding Shares7,216,000Free Float6,085,000Market Cap$19.99 million OptionableNot Optionable Beta3.09 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:NRXS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeurAxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.